February 2, 2011
News
Decay assessment and prevention
by
ken
Florida-based biopharmaceutical company Oragenics, Inc. (OTCBB: ORNI) announced its intention to commence a second phase 1 clinical trial of SMaRT Replacement Therapy. The Company has retained PRA International as the Clinical Research Organization (CRO) for clinical trials management services related…
View Print Edition
View Digital Edition
View Special Edition